Elanco Animal Health Incorporated (NYSE:ELAN) Receives $17.57 Consensus Target Price from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $17.57.

A number of research analysts have weighed in on the company. Piper Sandler decreased their price target on Elanco Animal Health from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Monday, July 1st. Barclays cut their price target on shares of Elanco Animal Health from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Friday, June 28th.

Insiders Place Their Bets

In related news, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now directly owns 81,094 shares of the company's stock, valued at approximately $1,204,245.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 100,000 shares of the company's stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now owns 145,000 shares of the company's stock, valued at approximately $1,886,450. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael J. Harrington bought 3,500 shares of the company's stock in a transaction on Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now owns 81,094 shares of the company's stock, valued at $1,204,245.90. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company's stock.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its position in shares of Elanco Animal Health by 2.9% during the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company's stock valued at $753,945,000 after buying an additional 1,431,665 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Elanco Animal Health by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company's stock valued at $737,083,000 after acquiring an additional 467,196 shares during the period. Price T Rowe Associates Inc. MD grew its position in Elanco Animal Health by 4.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company's stock worth $360,425,000 after acquiring an additional 852,281 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Elanco Animal Health by 33.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company's stock worth $224,920,000 after purchasing an additional 3,816,514 shares during the period. Finally, Ancora Advisors LLC boosted its stake in shares of Elanco Animal Health by 1.4% during the first quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company's stock valued at $173,239,000 after purchasing an additional 143,326 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Down 1.7 %

Shares of ELAN traded down $0.26 on Friday, reaching $15.09. 3,600,515 shares of the company's stock were exchanged, compared to its average volume of 4,795,414. Elanco Animal Health has a 12 month low of $8.52 and a 12 month high of $18.80. The business has a 50 day moving average price of $13.83 and a two-hundred day moving average price of $15.26. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $7.46 billion, a P/E ratio of -5.69, a price-to-earnings-growth ratio of 1.54 and a beta of 1.40.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.06. The business had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.18 EPS. Research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.